The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
2018; American Association for the Advancement of Science; Volume: 359; Issue: 6371 Linguagem: Inglês
10.1126/science.aao3290
ISSN1095-9203
AutoresVyara Matson, Jessica Fessler, Riyue Bao, Tara Chongsuwat, Yuanyuan Zha, Maria‐Luisa Alegre, Jason J. Luke, Thomas F. Gajewski,
Tópico(s)Immunotherapy and Immune Responses
ResumoAnti-PD-1-based immunotherapy has had a major impact on cancer treatment but has only benefited a subset of patients. Among the variables that could contribute to interpatient heterogeneity is differential composition of the patients' microbiome, which has been shown to affect antitumor immunity and immunotherapy efficacy in preclinical mouse models. We analyzed baseline stool samples from metastatic melanoma patients before immunotherapy treatment, through an integration of 16
Referência(s)